Eduard Enrico Holdener
Presidente en NOVIMMUNE SA .
Cargos activos de Eduard Enrico Holdener
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
NOVIMMUNE SA | Presidente | 01/02/2008 | - |
Director Ejecutivo | 21/12/2015 | - | |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Director/Miembro de la Junta | 01/01/2009 | - |
Swiss Cancer Foundation | Director/Miembro de la Junta | - | - |
Historial de carrera de Eduard Enrico Holdener
Antiguos cargos conocidos de Eduard Enrico Holdener.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
HBM HEALTHCARE INVESTMENTS AG | Director/Miembro de la Junta | 01/01/2008 | 18/06/2021 |
PAREXEL INTERNATIONAL CORPORATION | Director/Miembro de la Junta | 01/01/2008 | 29/09/2017 |
Independent Dir/Board Member | 01/01/2008 | 29/09/2017 | |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Director Técnico/Científico/I+D | 01/02/2008 | 01/02/2008 |
ROCHE HOLDING AG | Corporate Officer/Principal | 01/01/1995 | 01/01/2007 |
TIGENIX NV | Director/Miembro de la Junta | - | - |
Independent Dir/Board Member | - | - | |
Ipsen Bioinnovation Ltd.
Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. | Director/Miembro de la Junta | 01/01/2008 | - |
Formación de Eduard Enrico Holdener.
University of Basel | Doctorate Degree |
University of Zurich | Doctorate Degree |
Estadísticas
Internacional
Suiza | 8 |
Estados Unidos | 2 |
Reino Unido | 2 |
Operativa
Director/Board Member | 6 |
Independent Dir/Board Member | 2 |
Doctorate Degree | 2 |
Sectorial
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
ROCHE HOLDING AG | Health Technology |
Empresas privadas | 8 |
---|---|
PAREXEL International Corp.
PAREXEL International Corp. Miscellaneous Commercial ServicesCommercial Services PAREXEL International Corp. provides biopharmaceutical services. It offers clinical research and logistics, medical communications, consulting, commercialization and advanced technology products and services for pharmaceutical, biotechnology and medical device industries. The company was founded in 1983 and is headquartered in Newton, MA. | Commercial Services |
Novimmune SA
Novimmune SA Medical/Nursing ServicesHealth Services Novimmune SA discovers and develops antibody-based drugs targeted for the treatment of inflammatory diseases, immune-related disorders and cancer. The company was founded by Bernard Mach in 1998 and is headquartered in Plan-les-Ouates, Switzerland. | Health Services |
Ipsen Bioinnovation Ltd.
Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
HBM Healthcare Investments AG
HBM Healthcare Investments AG Investment ManagersFinance HBM Healthcare Investments AG is a listed investment company which invests worldwide, primarily focusing on Europe, Asia and North America, in private and public companies in the human medicine, biotechnology, medical technology and diagnostics sectors, and related areas. It aims to invest mainly in a form of equity, but also considers convertible bonds, debt securities and derivatives. The investment focus is on later stage companies, and participates in follow-on investment rounds, also acquiring majority stake in target companies. It invests also in other funds. | Finance |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Health Technology |
TiGenix NV
TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
Swiss Cancer Foundation |